Abraham Morgentaler, MD, FACS, describes the phenomenon of testosterone flare following prostate cancer treatment with luteinizing hormone-releasing hormone (LHRH) agonists and argues that this flare does not necessarily cause disease progression. He also discusses the effects of testosterone therapy in patients with untreated prostate cancer.
Read More
Abraham Morgentaler, MD, explains new concepts that could subvert the long-held belief that high levels of testosterone exacerbate prostate cancer growth. He discusses the androgen saturation model, as well as the benefits of testosterone therapy for patients’ quality of life.
Read More
Dr. Karim Fizazi presented “Update on Mechanisms of Resistance in Castration-Resistant Prostate...
Read More
Dr. Karim Fizazi and Dr. Bertrand Tombal presented a debate on “Hormone-Naive Metastatic Prostate...
Read More
E. David Crawford, MD presented “ADT: Mechanisms of CV Disease” at the 6th Symposium on the...
Read More
Dr. Jehonathan Pinthus presented at the 26th International Prostate Cancer Update on Friday,...
Read More
Dr. Lawrence I. Karsh spoke at the 21st annual Scottsdale Prostate Cancer Symposium 2016 on...
Read More
